Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Heart Failure

ClinicalTrials.gov lists 5,838 trials for Heart Failure or a narrower condition beneath it. Abbott Medical Devices has the most among industry and government lead sponsors, with 104.

MeSH D006333 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 227 Phase 1/2 Phase 1/2 113 Phase 2 Phase 2 396 Phase 2/3 Phase 2/3 92 Phase 3 Phase 3 341 Phase 4 Phase 4 449 Not applicable Not applicable 2,323 Observational Observational 1,892 Phase 1 Phase 1 227 Phase 1/2 Phase 1/2 113 Phase 2 Phase 2 396 Phase 2/3 Phase 2/3 92 Phase 3 Phase 3 341 Phase 4 Phase 4 449 Not applicable Not applicable 2,323 Observational Observational 1,892

Trials per phase (log scale)

1 more section with rows

5,569 of the 5,838 trials are tagged with Heart Failure itself; the rest are tagged with a narrower condition beneath it.

Get the Heart Failure report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Heart Failure trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 18 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 348

1990: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 1992: 2 trials (Observational 2) 1993: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 1994: 3 trials (Phase 3 2, Phase 2 1) 1995: 1 trials (Observational 1) 1996: 5 trials (Observational 3, Not applicable 1, Phase 3 1) 1997: 10 trials (Observational 4, Phase 3 5, Phase 2 1) 1998: 11 trials (Observational 6, Not applicable 1, Phase 3 3, Phase 2/3 1) 1999: 12 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 2) 2000: 17 trials (Observational 9, Not applicable 2, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 1/2 1) 2001: 32 trials (Observational 9, Not applicable 11, Phase 4 3, Phase 3 7, Phase 2 2) 2002: 42 trials (Observational 11, Not applicable 7, Phase 4 6, Phase 3 11, Phase 2 5, Phase 1/2 2) 2003: 78 trials (Observational 15, Not applicable 18, Phase 4 13, Phase 3 13, Phase 2/3 5, Phase 2 10, Phase 1/2 3, Phase 1 1) 2004: 101 trials (Observational 25, Not applicable 26, Phase 4 17, Phase 3 7, Phase 2/3 3, Phase 2 19, Phase 1/2 2, Phase 1 2) 2005: 111 trials (Observational 28, Not applicable 34, Phase 4 10, Phase 3 14, Phase 2/3 5, Phase 2 9, Phase 1/2 2, Phase 1 9) 2006: 124 trials (Observational 36, Not applicable 23, Phase 4 23, Phase 3 12, Phase 2/3 6, Phase 2 11, Phase 1/2 5, Phase 1 8) 2007: 176 trials (Observational 55, Not applicable 47, Phase 4 21, Phase 3 22, Phase 2/3 6, Phase 2 12, Phase 1/2 5, Phase 1 8) 2008: 156 trials (Observational 51, Not applicable 39, Phase 4 21, Phase 3 12, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 15) 2009: 189 trials (Observational 56, Not applicable 63, Phase 4 22, Phase 3 8, Phase 2/3 6, Phase 2 21, Phase 1/2 6, Phase 1 7) 2010: 193 trials (Observational 55, Not applicable 73, Phase 4 17, Phase 3 8, Phase 2/3 1, Phase 2 27, Phase 1/2 7, Phase 1 5) 2011: 238 trials (Observational 65, Not applicable 99, Phase 4 15, Phase 3 15, Phase 2/3 9, Phase 2 13, Phase 1/2 7, Phase 1 15) 2012: 198 trials (Observational 66, Not applicable 72, Phase 4 15, Phase 3 15, Phase 2/3 4, Phase 2 12, Phase 1/2 7, Phase 1 7) 2013: 223 trials (Observational 66, Not applicable 95, Phase 4 16, Phase 3 12, Phase 2/3 4, Phase 2 20, Phase 1/2 6, Phase 1 4) 2014: 262 trials (Observational 89, Not applicable 111, Phase 4 15, Phase 3 11, Phase 2/3 7, Phase 2 13, Phase 1/2 3, Phase 1 13) 2015: 228 trials (Observational 92, Not applicable 89, Phase 4 12, Phase 3 9, Phase 2/3 3, Phase 2 9, Phase 1/2 5, Phase 1 9) 2016: 274 trials (Observational 86, Not applicable 110, Phase 4 28, Phase 3 11, Phase 2/3 7, Phase 2 20, Phase 1/2 2, Phase 1 10) 2017: 281 trials (Observational 77, Not applicable 126, Phase 4 24, Phase 3 12, Phase 2 25, Phase 1/2 4, Phase 1 13) 2018: 289 trials (Observational 88, Not applicable 128, Phase 4 18, Phase 3 15, Phase 2/3 3, Phase 2 15, Phase 1/2 6, Phase 1 16) 2019: 267 trials (Observational 84, Not applicable 126, Phase 4 17, Phase 3 15, Phase 2 12, Phase 1/2 4, Phase 1 9) 2020: 273 trials (Observational 99, Not applicable 111, Phase 4 20, Phase 3 10, Phase 2/3 4, Phase 2 14, Phase 1/2 6, Phase 1 9) 2021: 334 trials (Observational 130, Not applicable 134, Phase 4 23, Phase 3 11, Phase 2/3 4, Phase 2 16, Phase 1/2 5, Phase 1 11) 2022: 314 trials (Observational 123, Not applicable 141, Phase 4 10, Phase 3 6, Phase 2/3 1, Phase 2 17, Phase 1/2 5, Phase 1 11) 2023: 341 trials (Observational 134, Not applicable 151, Phase 4 16, Phase 3 12, Phase 2/3 4, Phase 2 15, Phase 1/2 4, Phase 1 5) 2024: 348 trials (Observational 108, Not applicable 160, Phase 4 23, Phase 3 18, Phase 2 22, Phase 1/2 4, Phase 1 13) 2025: 336 trials (Observational 115, Not applicable 151, Phase 4 13, Phase 3 14, Phase 2/3 2, Phase 2 23, Phase 1/2 6, Phase 1 12)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 306
2025 336
2024 348
2023 341
2022 314
2021 334
2020 273
2019 267
2018 289
2017 281

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 350 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 481 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 3,433 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Heart Failure trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 227
Phase 1/2 113
Phase 2 396
Phase 2/3 92
Phase 3 341
Phase 4 449
Not applicable 2,323
Observational 1,892
Expanded access 5

How many Heart Failure trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 260
Recruiting 710
Enrolling by invitation 75
Active, not recruiting 206
Completed 2,941

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Heart Failure trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Abbott Medical Devices 104
Medtronic Cardiac Rhythm and Heart Failure 98
AstraZeneca 56
Boston Scientific Corporation 52
National Heart, Lung, and Blood Institute (NHLBI) 48

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Heart Failure? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
BMS-512148 47
.spironolactone 37
Levosimendan 30
VALSARTAN 22
Enalapril 21

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Furosemide-IR 50
Empagliflozine 48
Valsartan and Sacubitril 48
Nesritide (2+0.01) 33
LCZ696A 27

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Heart Failure trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Cardiac failure 10,970 100
Pneumonia 4,356 127
Invasive cancer of any type 3,234 1
Death 3,224 97
Other 3,118 15

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Heart Failure? (9,240)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease. American journal of cardiovascular drugs : drugs, devices, and other interventions 2026 Yes
Mechanistic Basis for Differential Effects of Interatrial Shunt Treatment in HFrEF vs HFpEF: The RELIEVE-HF Trial. JACC. Cardiovascular imaging 2026 Yes
Enhancing Sweat Rate for In-Hospital and Home-Based Decongestive Therapy. Journal of cardiac failure 2026 Yes
Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial. JACC. Heart failure 2026 Yes
Finerenone and NYHA Functional Class in Heart Failure: The FINEARTS-HF Trial. JACC. Heart failure 2026 Yes

Showing 5 of 9,240 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages